Alkermes Expands Senior Management Team

  Alkermes Expands Senior Management Team

    – Appoints Serge Stankovic, M.D., as Senior Vice President of Clinical
    Development and Medical Affairs, and Peter Norman as Vice President of
                             Government Affairs –

Business Wire

DUBLIN -- September 30, 2013

Alkermes plc (NASDAQ: ALKS) today announced that it has expanded its senior
management team by appointing two industry veterans to newly created roles.
Srdjan (Serge) Stankovic, M.D., MSPH, will serve as Senior Vice President of
Clinical Development and Medical Affairs, and Peter Norman has joined the
company as Vice President of Government Affairs and Policy.

“We are very pleased to welcome Serge and Pete – two proven leaders whose
expertise will contribute to Alkermes’ next stage of growth,” said Richard
Pops, Chief Executive Officer of Alkermes. “As our portfolio of new medicines
expands, we are responding by strengthening our capabilities in two areas
critical for our future: global clinical development and government affairs.”

Dr. Serge Stankovic will be responsible for Alkermes’ Clinical Development and
Medical Affairs function, which advances and implements the clinical
development programs for the company’s pipeline of drug candidates. He will
serve on the senior management team at Alkermes and report to Elliot Ehrich,
M.D., Senior Vice President of Research & Development and Chief Medical

“I am very enthusiastic about leading the clinical development programs during
this exciting time when Alkermes is expanding its pipeline,” said Dr.
Stankovic. “I look forward not only to making progress with the range of
clinical studies that are underway and planned for drug candidates, but also
to achieving the ultimate goal of delivering valuable medicines that make a
difference for patients.”

Mr. Peter Norman will lead Alkermes’ U.S. Government Affairs and Policy
function, ranging from activities at federal and state levels, to interactions
with professional and patient organizations. He will serve on the senior
management team at Alkermes and report to Kathryn Biberstein, Senior Vice
President, Chief Legal Officer and Chief Compliance Officer.

“I am excited to join Alkermes at a time when there are so many emerging
opportunities to connect the company’s medicines with policy and advocacy
initiatives to impact patients, healthcare systems and the public health,”
said Mr. Norman. “Alkermes is poised to advance innovative solutions for
chronic central nervous system (CNS) diseases that significantly impact both
health systems and society. I also look forward to exploring new public
affairs and policy strategies for enhancing adoption of, and access to, the
company’s products.”

Dr. Serge Stankovic brings more than 20 years of research and development
(R&D) experience to Alkermes. He has led multidisciplinary development teams
for small molecules and biologics in the therapeutic areas of psychiatry,
neurology, oncology, pain and inflammation, respiratory medicine,
cardiovascular medicine and stem cell therapy. Most recently, Dr. Stankovic
held the position of Senior Vice President and Head of Global Clinical
Development for Teva Pharmaceuticals. He was appointed to this role following
Teva’s acquisition of Cephalon, Inc., where he served as Senior Vice
President, Worldwide Clinical Research, and was a member of the Executive
Committee. In addition, Dr. Stankovic has held various executive management
positions in the R&D organizations of UCB Pharma, Johnson & Johnson, Neurogen
Corporation and Forest Laboratories, Inc., and is credited with several major
new drug approvals, including KEPPRA^® and NUVIGIL^®. Dr. Stankovic completed
his training in psychiatry at the University of Belgrade, Yugoslavia and his
epidemiology training at the University of Alabama in Birmingham.

Mr. Peter Norman is a seasoned government affairs leader with significant
experience in legislative and regulatory efforts as well as interactions with
patient groups and healthcare coalitions on behalf of biopharmaceutical
companies. He has worked on public policy strategies related to a range of
pharmaceutical products, including drugs for Alzheimer’s disease, obesity and
diabetes, in addition to major healthcare issues, such as Medicare and
Medicaid reimbursement, healthcare reform, DEA-controlled substance scheduling
and biosimilars legislation. Most recently, Mr. Norman was head of the
Washington, D.C. office of Eisai, Inc., where he directed government affairs
and policy. Previously, he held government affairs positions for Amylin
Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Novo Nordisk; and the
Biotechnology Industry Organization (BIO). Mr. Norman earned a Juris Doctor
from the University of Toledo College of Law in Ohio.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company that
applies its scientific expertise and proprietary technologies to develop
innovative medicines that improve patient outcomes. The company has a
diversified portfolio of more than 20 commercial drug products and a
substantial clinical pipeline of product candidates that address central
nervous system (CNS) disorders such as addiction, schizophrenia and
depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center
in Waltham, Massachusetts; a research and manufacturing facility in Athlone,
Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington,
Ohio. For more information, please visit Alkermes’ website at

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. You are cautioned that forward-looking statements are inherently
uncertain. Although the company believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its business and
operations, the forward-looking statements are neither promises nor guarantees
and they are necessarily subject to a high degree of uncertainty and risk.
Actual performance and results may differ materially from those projected or
suggested in the forward-looking statements due to various risks and
uncertainties, including those risks described in the company’s most recent
Annual Report on Form 10-K and 10-K/A, which are filed with the Securities and
Exchange Commission (“SEC”) and are available on the SEC’s website at The information contained in this press release is provided by
the company as of the date hereof, and, except as required by law, the company
disclaims any intention or responsibility for updating any forward-looking
information contained in this press release.

KEPPRA^® is a registered trademark of the UCB Group of Companies. NUVIGIL^® is
a trademark of Cephalon, Inc., or its affiliates.


For Investors: Rebecca Peterson, +1-781-609-6378
For Media: Jennifer Snyder, +1-781-609-6166
Press spacebar to pause and continue. Press esc to stop.